Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvo crawled time : 19:00 save search
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Published: 2024-03-08 (Crawled : 19:00) - globenewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
| Email alert
Add to watchlist
wegovy obesity disease approved risk cardiovascular
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: 2024-02-06 (Crawled : 19:00) - globenewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: -0.54%
H: 2.31%
C: 1.44%
Global Generic Drugs Business Analysis Report 2023-2030: Small-molecule Generic Drugs Account for a Lion's Share, Biosimilars Exhibit Fastest Growth
Published: 2023-10-23 (Crawled : 19:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 3.4K
|
n/a
|
| O: -44.44%
H: 60.0%
C: -20.0%
AZNCF | $138.24 -1.36% -4.19% 800
|
Health Technology
|
| O: 1.37%
H: 1.36%
C: 1.36%
VTRS | $11.12 0.18% 0.09% 2.3M
|
Health Technology
|
| O: 0.45%
H: 2.46%
C: 1.67%
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: -0.79%
H: 1.41%
C: 1.21%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
BAX | $39.65 0.33% -1.19% 2.3M
|
Health Technology
|
| O: 0.2%
H: 0.9%
C: -1.05%
ABT | News | $105.27 -0.6% -0.38% 5.9M
|
Health Technology
|
| O: -1.82%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 3.6M
|
Health Technology
|
| O: 0.38%
H: 2.31%
C: 2.02%
report business global growth
Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: -0.84%
H: 0.19%
C: -0.13%
il-22 obesityweek pharma control preclinical
Novo Nordisk and UNICEF to extend joint initiative to prevent global childhood obesity
Published: 2023-09-20 (Crawled : 19:00) - globenewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: -1.92%
H: 0.61%
C: -1.74%
obesity initiative global
Global Insulin Pen Market Projected to Reach $73.39 Billion by 2028 with Steady CAGR of 5.25% during 2023-2028
Published: 2023-07-28 (Crawled : 19:00) - prnewswire.com
TRUMY | $16.507 -1.1% 0.79% 34K
|
Manufacturing
| Email alert
Add to watchlist
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
| Email alert
Add to watchlist
TRUMF | $16.928 -1.08% -17.59% 1.9K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
reach global insulin market
Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024
Published: 2023-03-14 (Crawled : 19:00) - biospace.com/
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: 1.15%
H: 0.65%
C: 0.56%
diabetes living insulin
Trading in Novo Nordisk shares by board members, executives and associated persons
Published: 2023-02-02 (Crawled : 19:00) - globenewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: 2.58%
H: 1.24%
C: 0.77%
Novo Nordisk A/S – Share repurchase programme
Published: 2022-11-30 (Crawled : 19:00) - globenewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: 1.25%
H: 0.2%
C: -0.02%
repurchase
Global $19 Billion Home-Use Insulin Delivery Devices Markets, 2015-2020 & 2021-2030
Published: 2021-12-20 (Crawled : 19:00) - prnewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: 1.2%
H: 1.62%
C: 1.37%
MDT | $79.19 0.14% -0.57% 5.1M
|
Health Technology
|
| O: 0.45%
H: 2.78%
C: 1.68%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.2%
H: 0.74%
C: 0.33%
BDX | $233.15 0.41% -0.86% 650K
|
Health Technology
|
| O: 0.57%
H: 0.63%
C: -0.8%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.76%
H: 0.67%
C: 0.45%
PODD | $164.73 -0.92% -0.94% 590K
|
Health Technology
|
| O: 0.29%
H: 3.22%
C: 3.08%
device liver insulin
Novo Nordisk announces supply challenges for Wegovy® in the US
Published: 2021-12-17 (Crawled : 19:00) - globenewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
wegovy
Novo Nordisk A/S – Share repurchase programme
Published: 2021-11-29 (Crawled : 19:00) - globenewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: -1.04%
H: 1.43%
C: 0.79%
Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
Published: 2021-06-04 (Crawled : 19:00) - globenewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
| Email alert
Add to watchlist
therapy
Global Hematology Drugs Market (2021 to 2030) - COVID-19 Impact and Recovery
Published: 2021-04-13 (Crawled : 19:00) - prnewswire.com
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: 0.64%
H: 0.06%
C: -0.94%
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: 0.47%
H: 1.1%
C: -0.62%
covid drug
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.